Medication & Safety
Return and Refund Policy: What to Check Before You Buy
A clear return and refund policy tells you a lot about a seller before anything goes wrong. Here is what to check before...
Tirzepatide produces more weight loss than semaglutide. The trial figures point clearly that way, and most clinicians working in this area accept it.
But the two headline numbers people quote come from separate trials, and that matters more than most comparisons admit. This guide covers what each drug achieved, how reliable the comparison is, and which factors beyond the headline number should shape the decision.
The two drugs
Zepbound is tirzepatide, made by Eli Lilly, injected weekly, doses from 2.5 mg to 15 mg.
Wegovy is semaglutide, made by Novo Nordisk, injected weekly, target dose 2.4 mg.
Both are approved specifically for weight management, which distinguishes them from Mounjaro and Ozempic. Those contain the same two molecules but are approved for type 2 diabetes.
The mechanism difference
This is the substantive distinction between them.
Wegovy activates the GLP-1 receptor. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. It slows stomach emptying, signals fullness to your brain and prompts insulin release.
Zepbound activates GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), a second gut hormone released after eating that also stimulates insulin and appears to affect how fat tissue handles energy storage.
Hitting both receptors is the reason tirzepatide is described as a dual agonist. The additional GIP action seems to add effects on fat tissue and energy use that GLP-1 alone does not produce.
The numbers
| Zepbound (SURMOUNT-1) | Wegovy (STEP 1) | |
|---|---|---|
| Trial duration | 72 weeks | 68 weeks |
| Top dose result | 20.9 percent | 14.9 percent |
| Mid dose result | 19.5 percent at 10 mg | — |
| Low dose result | 15.0 percent at 5 mg | — |
| Placebo | 3.1 percent | 2.4 percent |
SURMOUNT-1 was published in the New England Journal of Medicine in 2022. STEP 1 was published in the same journal in 2021.
Read plainly, tirzepatide's 20.9 percent against semaglutide's 14.9 percent is a six percentage point gap. On a 100 kg starting weight, that is roughly 6 kg of difference.
Worth noting: tirzepatide's lowest dose, 5 mg, produced 15.0 percent. That essentially matches semaglutide's top-dose result.
Why the comparison needs care
These are separate trials. Different participants, different sites, different years, slightly different durations.
Cross-trial comparison is the weakest form of evidence for exactly this reason. Populations differ in starting weight, age distribution, ethnic mix and baseline health. Trial conduct differs. Placebo responses differed between these two studies, which is itself a signal that the populations were not identical.
The honest position is that tirzepatide very likely produces more weight loss than semaglutide, and the gap is probably substantial, but the precise six-point figure should not be treated as exact.
A direct head-to-head between them is the only thing that settles it properly, in the way STEP 8 settled semaglutide against liraglutide.
Side effects
Both share the profile of this drug class, driven by slowed stomach emptying.
Nausea, diarrhoea, vomiting and constipation dominate for both. Fatigue, abdominal pain and injection site reactions occur with both.
The general pattern across this field is that stronger effect brings more gastrointestinal disturbance. Tirzepatide's dual mechanism does not exempt it from that.
Serious risks are shared. Pancreatitis, gallbladder disease and the medullary thyroid carcinoma contraindication apply to both. Neither is used in pregnancy.
Tirzepatide has one additional consideration. It can reduce absorption of oral contraceptives, particularly around dose increases, so backup contraception needs discussing.
Dosing
Wegovy escalates over roughly 16 weeks to 2.4 mg. Zepbound escalates over roughly 20 weeks to 15 mg, in 2.5 mg steps.
Both are weekly injections, both refrigerated before use, both able to be given any time of day with or without food.
Zepbound offers more dose steps, which gives prescribers finer control for someone who is struggling with side effects or who reaches their goal at a lower dose.
Cost and supply
Both are expensive. Neither is registered in Pakistan.
Both have faced global supply shortages driven by weight loss demand. Semaglutide's shortages have been longer running. Tirzepatide's supply has been constrained since launch simply because demand outstripped manufacturing capacity.
For anyone in Pakistan, both arrive through import channels with the price volatility, verification difficulty and continuity risk that involves.
What actually decides it
If both were freely available and affordable, tirzepatide would be the stronger choice on the evidence. That is the straightforward reading.
They are not freely available here, which changes the question. SURMOUNT-1 ran 72 weeks. STEP 1 ran 68 weeks. Those results describe what happens when someone takes the drug continuously for well over a year.
An import chain that breaks at month four does not deliver a fraction of the result proportional to the time. Appetite returns, weight often follows, and restarting usually means re-escalating from a low dose.
Continuity is not a footnote to efficacy in this market. It is the main variable.
This is why registered options exist locally. METASLIM™ provides injection-free GLP-1 pathway support as sublingual drops, with a physician reviewing every order before dispatch. It is a physician-reviewed supplement rather than tirzepatide or semaglutide, so SURMOUNT-1 and STEP 1 figures do not apply to it and should never be presented as though they do. Its advantage is that it can actually be obtained and completed here, with medical oversight attached.
That oversight is worth weighing on its own. Our page on the doctor-guided approach explains why supervision matters more, not less, when the alternative is self-sourcing medication from informal channels.
This article covers the two brands approved specifically for weight management. For the underlying molecules compared at drug level, see semaglutide vs tirzepatide. For the diabetes-approved brand of tirzepatide, see Wegovy vs Mounjaro. Our full guide to Zepbound covers tirzepatide in detail.
The verdict
Tirzepatide produces more weight loss. The evidence supports it and the mechanism explains it.
The gap is probably close to six percentage points but should not be quoted as precise, because it comes from separate trials rather than a direct comparison.
Both are weekly injections with similar tolerability challenges, and neither is reliably obtainable in Pakistan.
Check availability and cash-on-delivery options if you want a program you can complete rather than a drug you can start.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.